NCT07260708 2025-12-19
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
Clinical Trials
9 trialsNCT06649656 2024-10-21
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT06413953 2024-07-03
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT03375983 2024-02-20
Plasmodium Immunotherapy for Advanced Cancers
CAS Lamvac Biotech Co., Ltd.
Phase 1/2 Recruiting
NCT05333276 2023-07-27
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05380882 2022-05-19
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT02561234 2021-11-05
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Aeglea Biotherapeutics
Phase 1/2 Completed
NCT01021072 2021-02-16
A First in Man Study of MABp1 in Patients With Advanced Cancers
Janssen Research & Development, LLC
Phase 1 Completed
NCT00836927 2019-02-18
MK-8669-038
Merck Sharp & Dohme LLC
Phase 2 Terminated